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Abstract
In gene therapy, a clinically relevant therapeutic effect
requires long-term expression of the desired gene at a
level sufficient to correct or at least alleviate the underly-
ing gene defect. One approach to achieve persistent as
well as high-level transgene expression in a significant
percentage of target cells would be to select cells ex-
pressing both the desired transgene and a linked select-
able gene – such as the human multi-drug resistance
(MDR1) gene – in a bicistronic vector. Because of its
accessibility, the skin is a very attractive target tissue to
select genetically modified cells, allowing topical appli-
cation of a selecting agent, thus minimizing potential
toxic side effects. Among the potential selecting drugs,
agents that block cell division, such as colchicine, are of
particular interest because the use of anti-mitotic drugs
takes advantage of the rapid keratinocyte (KC) turnover
in the epidermis and the need for continued proliferation
to substitute the KC lost due to selection. Before assess-
ing the therapeutic benefit of such an approach, several
key questions need to be answered in preclinical models:
(1) Does topical colchicine application achieve the de-
sired in vivo effect by blocking KC mitosis without elic-
iting unwanted toxic side effects? (2) Are MDR-trans-
duced (MDR+) human KC still able to proliferate and dif-
ferentiate when treated with colchicine? (3) Can MDR+
KC be enriched by topical selection? (4) Does topical
selection result in persistent transgene expression by
selecting KC stem cells expressing MDR? To answer
these questions and to test the feasibility of such an
approach both an in vitro skin equivalent and an in vivo
human skin graft model were developed in which MDR+
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KC were treated with different dosages of colchicine.
Quantitative and qualitative analyses of MDR expression
in human KC showed that topical colchicine treatment
selects high-level transgene expression in a high per-
centage of KC. Moreover, determination of transgene
copy numbers demonstrated that MDR+ KC progenitor
cells were enriched by topical selection resulting in long-
term expression of the transgene in the skin. Thus, in
summary, these models demonstrate that topical selec-
tion of MDR+ KC is a safe approach to efficiently enhance
long-term gene expression in the skin and holds future
promise for clinical gene therapy applications.
Copyright © 2004 S. Karger AG, Basel
Introduction
In gene therapy, a clinically relevant therapeutic effect
usually requires both highly efficient gene transfer to the
target tissue and a sufficient level of expression of the
inserted gene. Although retroviral vectors are able to sta-
bly integrate into the host genome, gene expression is
often lost or diminished in vivo over time [Palmer et al.,
1991; Strauss, 1994; Fenjves et al., 1996; Lange et al.,
1997]. Possible reasons include a failure to efficiently tar-
get long-lived progenitor cells (stem cells) and gene silenc-
ing of the integrated retroviral vector due to methylation
or histone acetylation [Chen et al., 1997; Bestor, 2000].
Therefore, to ensure a clinically meaningful, lasting thera-
peutic effect, strategies need to be developed which focus
on maintaining gene expression in a high percentage of
target cells. One approach would be to target cells trans-
duced with a selectable gene linked to the desired trans-
gene in a bicistronic vector. When treating with a cyto-
toxic drug, transduced cells protected by the selectable
gene would have a selective advantage, enriching trans-
duced progenitor cells and cells with increased transgene
expression. Attempts to select hematopoietic cells trans-
duced with a selectable gene often have failed due to the
high toxicity of systemic chemotherapy or the need of
higher initial transgene expression levels in the treated
cells [Allay et al., 1995, 1998; Havenga et al., 1999;
Machiels et al., 1999; Davis et al., 2000]. As a result, the
feasibility of in vivo selection of genetically modified cells
has been questioned [Brenner, 1999].
The skin is a very compelling organ for gene therapy
approaches [Taichman, 1994; Khavari, 1997; Pfützner
and Vogel, 2000]. KC, the primary cell type in the epider-
mis, are easily obtained and readily expanded from small
skin biopsy specimens allowing retroviral vector trans-
duction with high efficiency. Genetically modified KC
can be formed into artificial skin and then be grafted to
establish a functional, durable epidermis [Kolodka et al.,
1998; Pfützner et al., 2002]. Previously, the potential of
skin gene therapy to treat both skin and systemic diseases
has been shown [Gerrard et al., 1993; Fenjves et al., 1994;
Choate et al., 1996; White et al., 1998; Robbins et al.,
2001]. However, although gene expression from retroviral
vectors has been detected for prolonged periods in grafted
KC [Deng et al., 1997; Kolodka et al., 1998; Levy et al.,
1998; White et al., 1998], in vivo transgene expression
was frequently low or declined over time when assessed
quantitatively [Morgan et al., 1987; Gerrard et al., 1993;
Stockschlader et al., 1994; Fenjves et al., 1996; Choate et
al., 1997; White et al., 1998]. These results highlight the
need for a strategy to efficiently augment the number of
KC expressing the gene of interest.
One approach would be the topical application of an
agent targeting KC containing a selectable marker gene,
thereby minimizing possible systemic side effects. Since
the human epidermis is a tissue with high proliferative
activity and continuous renewal [Halprin, 1972; Gelfant,
1982], good candidate drugs for topical selection would be
anti-mitotic compounds that block cell division. When
topically applied, only KC transduced with the selectable
gene – including KC stem cells – will still be able to divide
and proliferate while non-transduced KC should be
blocked in mitosis and replaced by the transduced KC.
Thus, topical selection should also increase the percent-
ages of genetically modified KC that express a desired
transgene linked to the selectable gene.
To test this hypothesis, we transduced human KC with
the multidrug resistance (MDR1) gene. The human
MDR1 gene possesses several desirable characteristics for
topical selection of KC. First, the MDR gene is expressed
in several human tissues associated with secretory or bar-
rier functions, but not in KC [Thiebaut et al., 1987; Cor-
don-Cardo et al., 1990]. Second, it encodes a transmem-
brane glycoprotein that functions as an ATP-dependent
efflux transporter for many different cytotoxic com-
pounds, allowing greater flexibility in choosing an appro-
priate selecting drug [Endicott and Ling, 1989; Gottes-
man and Pastan, 1993; Higgins, 1993]. Third, since the
MDR gene encodes a human protein, unlike many other
selectable marker genes, it would not be expected to elicit
a host immune response. To assess the feasibility of MDR
selection for the skin, both an in vitro skin equivalent and
an in vivo grafting model were developed in order to
answer several key questions: (1) Does topical colchicine
application achieve the desired in vivo effect by blocking
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KC mitosis without eliciting unwanted toxic side effects?
(2) Are MDR-transduced (MDR+) human KC still able to
proliferate and differentiate when treated with colchi-
cine? (3) Can MDR+ KC be enriched by topical selection?
(4) Does topical selection result in persistent transgene
expression by targeting KC stem cells expressing MDR?
In the following, we will summarize and discuss the
results of our in vitro and in vivo experiments, which
have been published in detail previously [Pfützner et al.,
1999; Pfützner et al., 2002].
Material and Methods
Tissue Preparation
Human KC were obtained from newborn foreskin and cultured
in monolayers as described [Pfützner et al., 1999]. Transduction was
performed by incubation of first-passage KC with the human MDR-
expressing pHaMDR1/A-retroviral vector [Pastan et al., 1988]. Raft
cultures were generated by seeding transduced KC on de-epider-
mized, acellular dermis (basement membrane side up), prepared as
described [Pfützner et al., 1999]. For selection, different concentra-
tions (10 or 50 ng/ml) of colchicine were added every other day to
selected raft cultures, starting 2 days after seeding of KC. To assess
the proliferative capacity of raft culture KC, bromodeoxyuridine
(BrdU; 10 ÌM ) was incubated with raft organ cultures on day 7 for
4 h. Raft cultures consisting of MDR-transduced human KC and
fibroblasts were constructed by established methods [Parenteau et
al., 1992; Garlick and Taichman, 1994] and maintained at the air/
liquid interface for 3 days until grafting.
Animals
Grafting was performed on 4- to 5-week-old NIH male Swiss nu/
nu mice (Taconic Farms). All animals were housed and used in accor-
dance with NIH guidelines. Grafts were placed on the muscle fascia
on the back of the mice in correct anatomical orientation and cov-
ered with a dressing [Pfützner et al., 2002]. The dressing was changed
at 1 week and removed after 2 weeks. Different dosages of colchicine
cream (prepared as described [Pfützner et al., 2002]) were topically
applied either on mouse skin or grafts of human KC, 2–3 times/week
for up to 10 weeks, starting 4–5 weeks after grafting (in two mice
topical colchicine selection was initiated 12 weeks after grafting and
then continued for another 12 weeks).
Histology
Fixed tissue was paraffin embedded, and either stained with
hematoxylin and eosin or used for immunohistochemistry. Un-
stained paraffin-embedded sections were de-waxed, rehydrated and
rinsed in phosphate-buffered saline prior to the immunohistochemi-
cal staining procedure. For detection of MDR expression, tissue sec-
tions were also incubated in the antigen-unmasking agent Retrieve-
All (Signet, Dedham, Mass., USA), for 10–20 min at 92°C. Staining
was performed using a Vectastain Universal ABC-AP Kit and Vector
Red Alkaline Phosphatase Substrate Kit I according to the protocols
provided by the manufacturer (Vector Laboratories, Burlingame,
Calif., USA). Sections were incubated with antibodies against either
human MDR1 (C219; Signet), proliferating cell nuclear antigen
(PC10; Boehringer Mannheim, Indianapolis, Ind., USA), cytokeratin
10 (AXL7125; Accurate Chemical & Scientific Corporation, Westbu-
ry, N.Y., USA), filaggrin (BT-576; Biomedical Technologies, Stough-
ton, Mass., USA), overnight at 4°C, or human involucrin (MED-
CLA130; Accurate Chemical & Scientific Corporation), for 30 min at
room temperature [Pfützner et al., 1999; Pfützner et al., 2002]. Con-
trol samples were stained with corresponding isotype control anti-
bodies. S-phase nuclei incorporating BrdU were detected using an
alkaline-phosphatase-conjugated monoclonal anti-BrdU antibody
(Boehringer Mannheim) as described [Pfützner et al., 1999]. The
number of BrdU-positive nuclei in a basal or immediately suprabasal
position per unit length of 500 basal cells was determined by a
blinded observer.
Flow Cytometry Analysis
KC cell suspensions obtained either from cell culture monolayers
or from epidermal sheets harvested from raft cultures or grafts as
described [Pfützner et al., 1999, 2002] were assessed by fluorescence-
activated cell sorting (FACS) using a FACScan flow cytometer
equipped with CellQuest software (Becton-Dickinson, Mountain
View, Calif., USA). Antibodies used for detection of human MDR,
proliferating cell nuclear antigen, or HLA-A, -B or -C were MRK16
(Kamiya, Seattle, Wash., USA), PC10 (applied after permeabiliza-
tion of KC as described [Pfützner et al., 1999]) and anti-human
HLA-A, -B or -C conjugated to R-phycoerythrin (PharMingen, San
Diego, Calif., USA), respectively [Pfützner et al., 2002]. MRK16 and
PC10 incubation was followed by addition of goat anti-mouse sec-
ondary antibody conjugated to fluorescein isothiocyanate (Bio-
source, Camarillo, Calif., USA). All samples were compared to cells
stained with appropriate isotype control antibodies. For multicolor
analysis, cells were preincubated with saturating concentrations of
anti-FcRÁII/III (PharMingen). Propidium-iodide-permeable (nonvi-
able) cells were excluded from the analyses.
Quantitative Real-Time Polymerase Chain Reaction Analysis
By using a DNeasy tissue collection kit (Qiagen, Valencia, Calif.,
USA), DNA samples were obtained either from epidermal sheets of
harvested grafts or from first-passage nontransduced and transduced
KC serving as a negative and positive control, respectively. Real-time
polymerase chain reaction (PCR) was performed on an Applied Bio-
systems PRISM sequence detector and software version 1.7 (GIB-
CO/BRL and Applied Biosystems) using specific primers and probes
as described [Pfützner et al., 2002].
Results and Discussion
Topical Colchicine Treatment Results in a
Dose-Dependent Increase of KC Blocked in Mitosis
A very important issue is to show that topical selection
can achieve effective selection without causing unwanted
side effects. Compounds that inhibit mitosis, such as col-
chicine, may have important advantages over other drugs
because they have a wide therapeutic window, and doses
that are effective for selection might not cause extensive
cell death and necrosis in KC not expressing MDR. To
test if topical colchicine application can block KC mitosis
and to determine the optimal dose range for topical selec-
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Fig. 1. Topical titration of colchicine treat-
ment demonstrates dose-dependent effects
on mouse and human skin. HE-stained sec-
tions from nude mouse skin treated for 2
weeks with either vehicle control (a, !20),
or 200 (b, !20) and 500 Ìg/g colchicine (c,
!20) and from human skin grafts treated for
2 weeks with 200 Ìg/g (d, !40) of colchicine
cream. Treatment with 200 Ìg/g resulted in
acanthosis and marked increase in KC
blocked in mitosis in both mouse skin (450/
1,000 basal cells vs. 15/1,000 basal cells in
vehicle control) and human skin (66/1,000
basal cells vs. 8/1,000 basal cells). Higher
colchicine doses of 500 Ìg/g led to cellular
necrosis and ulceration.
Fig. 2. MDR+ KC are protected against the
cytotoxic effects of colchicine, maintaining
their proliferative activity and forming
a well-differentiated, stratified epidermis
when treated with colchicine. Immunohis-
tostaining of BrdU incorporation in MDR+
KC raft cultures harvested on day 7 showed
similar percentages of BrdU-positive cells in
rafts either not treated (a), 25.08 B 1.24%
(n = 3), or treated with 50 ng/ml colchicine
(b; both !40), 23.08 B 1.42%. Expression
of the early differentiation marker keratin 10
(c, d; !20) and the late differentiation
marker filaggrin (e, f; !40) in MDR+ KC
skin raft cultures on day 11 was comparable
in rafts either not treated (c, e) or treated
with 50 ng/ml colchicine (d, f).
tion of human KC grafted onto nude mice, both nude
mouse skin and human skin grafts were treated with dif-
ferent doses of colchicine cream (0–500 Ìg/g) for a period
of 2–4 weeks (3 times/week). Histological analyses
showed that topical application of colchicine cream re-
sulted in dose-dependent increases in the number of KC
blocked in mitosis with high doses (500 Ìg/g) leading to
abundant cell necrosis and total disruption of the epider-
mal architecture (fig. 1). Thus, topical treatment with
moderate doses of colchicine (100–200 Ìg/g) allows to
block KC division without causing unwanted toxic side
effects.
Human KC Transduced with the MDR Gene Are
Protected against the Cytotoxic Effects of Drug
Selection
The most well-known cytotoxic effect of colchicine is
the inhibition of the assembly of the microtubulin spin-
dle, thereby blocking cell division. However, colchicine
has additional toxic effects on cells. It can also disrupt the
cellular cytoskeleton and interfere with protein synthesis
and secretion, cell movement, cellular orientation and
stratification [Epstein et al., 1983; Thyberg and Moska-
lewski, 1985]. Thus, it is critical to determine if colchicine
may reduce the proliferative capacity of MDR+ KC or
impede their ability to form a differentiated epidermis
1
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and stratify. This is important because the MDR+ KC
will be required to replace the targeted KC lacking MDR.
To test the effects of topical colchicine selection on the
epidermal integrity, an in vitro skin raft culture, contain-
ing MDR+ KC seeded onto acellular dermis, was treated
with different concentrations of colchicine. When the pro-
liferative capacity was assessed by BrdU incorporation
assay and analysis of proliferating cell nuclear antigen
expression, there was no significant decrease in proliferat-
ing MDR+ KC in colchicine-treated skin rafts compared
to control samples (fig. 2a, b). Hematoxylin-eosin staining
performed on skin raft cultures after 11 and 14 days dem-
onstrated that KC transduced with a retroviral control
vector and treated with low doses of colchicine (10 ng/ml)
did not form an epidermis while MDR+ KC treated with
the same or higher doses (10–50 ng/ml) were still able to
develop a stratified epidermis similar in structure and
integrity to untreated controls [Pfützner et al., 1999]. Fur-
thermore, colchicine treatment of MDR+ KC showed
similar expression of early and late differentiation marker
genes in the correct epidermal layers compared to un-
treated control samples (fig. 2c–f). These results demon-
strate that KC expressing MDR maintain high prolifera-
tive activity and the ability to form a well-differentiated,
stratified epidermis during colchicine selection.
MDR+ KC Can Be Enriched by Topical Colchicine
Selection both in vitro and in vivo
The next question we asked was if MDR+ KC can be
enriched by topical colchicine selection. Initial in vitro
studies demonstrated a marked increase in MDR+ KC in
skin raft cultures treated with either 10 or 50 ng colchi-
cine/ml when compared to untreated raft cultures. This
was quantitatively confirmed by FACS analysis of KC
suspensions generated from skin raft cultures by enzymat-
ic treatment [Pfützner et al., 1999]. Application of colchi-
cine to raft cultures transduced with the control vector
resulted in the loss of all KC, ruling out the possibility that
colchicine treatment might induce or select for endoge-
nous MDR expression.
To test the feasibility of this approach in vivo, a graft-
ing model was utilized in which skin raft cultures com-
posed of human KC seeded onto a collagen gel embedded
with fibroblasts were grafted onto immunocompromised
mice [Kolodka et al., 1998]. This model allows efficient,
long-lasting skin engraftment, with growth factors and
adhesion molecules secreted by metabolically active fi-
broblasts in the skin raft possibly supporting the prolifera-
tion of the transplanted KC and anchoring the epidermis
to the dermis [Maas-Szabowski and Fusenig, 1996; Paren-
teau et al., 1996; Fleischmajer et al., 1998]. In grafts that
initially contained 50% MDR+ KC, a decrease in MDR+
KC was noticed over time with 34 B 5 and 24 B 11% of
transduced KC still showing MDR expression 2 and 4
weeks after grafting, respectively. At later time points, the
percentage of MDR+ KC continued to decline to 13 B 5
and 7 B 4% at 9 and 15 weeks, respectively [Pfützner et
al., 2002]. Thus, a significant loss of transgene expressing
KC occurred in vivo, as observed by others [Morgan et al.,
1987; Gerrard et al., 1993; Stockschlader et al., 1994;
Fenjves et al., 1996; Deng et al., 1997].
Our hypothesis is that treatment of the MDR+ grafts
with a chemotoxic agent like colchicine should lead to a
selective growth advantage of MDR+ KC and thereby
prevent the loss of gene expression. Based on the results of
colchicine dose titration onto mouse and human skin, we
decided to treat MDR+ KC grafts with colchicine dosages
of either 100 or 200 Ìg/g (3 times/week) to determine if
topical application of colchicine would select MDR+ KC.
Seven weeks after grafting skin raft cultures that con-
tained 50% MDR+ KC, grafts treated with control cream
contained only 20 B 9% MDR+ KC, while colchicine
treatment (100 or 200 Ìg/g colchicine) increased the per-
centages of MDR+ KC in the grafts to 41 B 24 and 58 B
22%, respectively [Pfützner et al., 2002]. Since the higher
dose of 200 Ìg/g resulted in a significant rise in MDR+
KC with large segments of the graft positive for MDR
expression by immunohistochemistry, this dose was cho-
sen for longer-term studies.
Continued selection of MDR+ KC grafts with 200 Ìg/g
showed that 9 weeks after grafting (representing approxi-
mately 3 epidermal turnovers), colchicine treatment had
resulted in an increased percentage of 50 B 26% (me-
dian = 40%) MDR+ KC compared to 13 B 5% (me-
dian = 10%) in the controls [Pfützner et al., 2002]. Fifteen
weeks after grafting, only 7 B 4% KC (median = 8%) of
the controls showed MDR expression, with 2 grafts exper-
iencing a complete loss of MDR-positive cells (fig. 3a, b).
On the other hand, colchicine treatment resulted in a ten-
fold-increased MDR expression (44 B 15%) of the KC
(median = 46%). The FACS data were confirmed by
immunohistostaining that showed MDR expression in up
to 50% of the human KC, while much smaller percentages
of MDR+ KC were present in vehicle-treated controls.
Thus, MDR+ human KC can be selected in vivo by topi-
cal colchicine application leading to a dose-dependent
increase in MDR+ KC whereas control grafts show a loss
of MDR expression over time. Interestingly, colchicine
treatment also selected MDR+ KC that expressed in-
creased amounts of MDR transgene per cell when com-
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Fig. 3. Topical colchicine selection increases
the percentage of MDR+ KC and MDR
expression level over time. FACS analysis of
epidermal cell suspensions generated from
MDR+ KC grafts revealed a continuous de-
cline in the percentage of MDR+ KC in
grafts treated with vehicle control ([), while
treatment with colchicine (200 Ìg/g) ini-
tiated 4 weeks after grafting (F) resulted in a
significant increase in MDR+ KC (P; a).
FACS analysis of grafts harvested after 15
weeks demonstrated both an increase in
MDR+ KC and level of MDR expression
(FL-1 channel) in MDR+ KC grafts treated
with colchicine (right) compared to un-
treated (middle) and isotype (left) controls
(b).
pared to vehicle-treated KC, as could be demonstrated by
FACS analysis (fig. 3b). The mean fluorescence intensity
of MDR expression in the FL1 channel (detection of fluo-
rescein isothiocyanate antibody bound to anti-MDR anti-
body) was 16 B 3 for colchicine-treated KC compared to
11 B 2 for vehicle-treated grafts, a 30% increase with col-
chicine treatment.
We also demonstrated that colchicine treatment could
select increased percentages of MDR+ KC even when ini-
tiated at much later time points after grafting. Two
MDR+ KC grafts treated with vehicle control cream for
12 weeks (a point in time when MDR+ KC in control
grafts would be expected to decline from 50% down to
approximately 9%) were switched to colchicine treatment
(200 Ìg/g, 2 times/week) for another 12 weeks. Following
this selection, FACS analysis revealed elevated numbers
of MDR+ KC (35 and 34%, respectively) [Pfützner et al.,
2002]. Thus, 24 weeks after grafting (8 epidermal turn-
over cycles), colchicine selection – initiated when only a
low percentage of MDR+ KC is present – is able to sub-
stantially increase the number of MDR+ KC, demonstrat-
ing that a small number of MDR+ KC can be expanded
by topical selection.
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Fig. 4. Topical colchicine selection of MDR+ KC significantly
increases transgene copy numbers in grafts. Determination of the rel-
ative MDR1 gene copy number in MDR+ KC grafts by quantitative
real-time PCR demonstrated significantly increased transgene copy
numbers in grafts treated with colchicine after 15 weeks compared to
vehicle-control-treated grafts. Normal human KC lacking the retrovi-
ral vector transgene (right) served as a negative control.
Topical Colchicine Selection Increases Transgene
Copy Numbers in Treated Grafts Suggesting
Enrichment for MDR+ KC Progenitor Cells
Since the epidermis represents a highly proliferative
tissue showing an epidermal turnover cycle of F21 days
in humans [Halprin, 1972; Gelfant, 1982], KC progenitor
cells have to carry the transgene to ensure a sustained high
level of gene expression. Immunohistochemistry and
FACS analysis of MDR+ KC grafts demonstrated that
topical selection resulted in long-term, enhanced trans-
gene expression at 15 weeks or approximately 5 epidermal
turnover cycles (time frame of 105 days) while control-
vehicle-treated grafts showed significant loss of MDR+
KC (fig. 3a). This suggests that MDR+ KC progenitors
have been enriched by colchicine treatment of the grafts.
Consequently, the percentage of human KC containing
the MDR gene would be increased in colchicine-treated
grafts compared to control grafts. Since we cannot experi-
mentally determine if individual KC contain an inte-
grated MDR gene, quantitative real-time PCR allows us
to determine how many MDR genes are present in a
defined population of KC, indicating if there are differ-
ences between both groups of grafts. We therefore pre-
pared genomic DNA from MDR+ KC harvested 15 weeks
after grafting and determined the relative copy number of
the MDR transgene, normalized to the endogenous hu-
man hematopoietic cell kinase gene. Compared to the
MDR+ KC skin raft cultures at the time of grafting, the
colchicine-treated MDR+ KC grafts contained a relative
MDR copy number of 1.14 B 0.41 while the vehicle-
treated grafts had a significantly lower relative MDR copy
number of 0.34 B 0.16 (fig. 4). Thus, KC in colchicine-
treated grafts contain 3–4 times more MDR transgenes at
15 weeks than vehicle-treated grafts. When the PCR
results are compared to the percentage of MDR+ KC
determined by FACS in the different treatment groups
(fig. 3a), these data argue that colchicine selection in-
creases the percentages of MDR+ KC, primarily by ex-
panding the population of KC progenitor cells that con-
tain the MDR gene. Only KC progenitor cells expressing
the MDR protein are able to divide, proliferate, and re-
populate the epidermis in the presence of colchicine,
while KC progenitors that lack MDR protein will be
blocked in mitosis and eventually undergo apoptosis
[Tsukidate et al., 1993; Bonfoco et al., 1995]. Additional-
ly, the low percentage of MDR+ KC in vehicle-treated
grafts after 15 weeks indicates that initially only a small
percentage of the KC progenitor cells (!7%) may have
been transduced with MDR during ex vivo culture.
One tremendous advantage of the skin compared to
other tissues is that topical selection allows high local con-
centrations of the selecting agent in the target tissue while
minimizing unwanted systemic effects. Although the per-
centage of MDR+ KC in untreated grafts declined over
time, we could demonstrate that topical colchicine selec-
tion can reverse this decline and significantly increase
both the percentage of MDR+ KC and the transgene
expression level per cell. Of note, this was not a short-term
effect but was shown to be persistent for a least 15 weeks,
representing 5 epidermal turnovers. Given the problem of
persistent in vivo expression of a desired gene at high lev-
els in gene therapy studies [Gottesman et al., 2000; Licht
et al., 2002], our approach of topical selection for MDR1
gene expression in KC could pave the way for elevated
and durable gene expression in the skin. However, impor-
tant questions still remain to be answered, for example
whether the maximum percentage of MDR+ KC can be
increased to 150%, the percentage achieved in this study,
by optimizing the colchicine dosing schedule and increas-
ing the duration of treatment. The question of what will
happen to the percentage of MDR+ KC after long-term
colchicine treatment is discontinued should also be solved
in future studies. If colchicine has in fact increased the
percentage of KC progenitor cells containing and express-
ing MDR, then the percentage of MDR+ KC should con-
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tinue to be elevated in the absence of colchicine selection.
Based on the results presented here, we anticipate that
topical transgene selection holds great promise for future
applications in clinical skin gene therapy trials that re-
quire significant levels of gene expression in a high per-
centage of KC.
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